97 related articles for article (PubMed ID: 8651041)
21. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
24. Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.
Viallet J; Ayoub J; Rousseau P; Souhami L; Hohneker J; Shepherd F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):64-71; discussion 71-2. PubMed ID: 7973771
[TBL] [Abstract][Full Text] [Related]
25. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
26. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
Vokes EE; Rosenberg R; Jahanzeb M; Craig J; Gralla R; Belani C; Jones S; Bigley J; Hohneker J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PubMed ID: 7973767
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of inoperable non-small cell bronchogenic carcinoma with a combination of cisplatin and vinorelbine--preliminary evaluation].
Adam Z; Coupková H; Kolek V; Kucera M; Loffelman L; Martinez A; Nováková L; Průsa P; Reiterer P; Rozánek P; Skalová B; Skricková J; Spelda S; Sturza V; Vorlícek J; Wurst F
Vnitr Lek; 1996 Mar; 42(3):175-80. PubMed ID: 8686206
[TBL] [Abstract][Full Text] [Related]
28. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
29. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
30. [Vinorelbine for non-small cell lung cancer].
Seto T
Nihon Rinsho; 2002 May; 60 Suppl 5():353-8. PubMed ID: 12101688
[No Abstract] [Full Text] [Related]
31. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
Soria JC; Brisgand D; Le Chevalier T
Ann Oncol; 2001 Dec; 12(12):1667-70. PubMed ID: 11843242
[TBL] [Abstract][Full Text] [Related]
32. [Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma].
Richardet E; Carranza L; Uribe A; Tolocka H; Cresta C; Uribe E; Uribe M
Rev Fac Cien Med Univ Nac Cordoba; 1995; 53(1):27-32. PubMed ID: 8602450
[TBL] [Abstract][Full Text] [Related]
33. Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1).
Crawford J; Chang AY; Gralla RJ; Souquet PJ; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):22-4. PubMed ID: 8610233
[No Abstract] [Full Text] [Related]
34. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC).
Depierre A; Lemarie E; Dabouis G; Garnier G; Jacoulet P; Dalphin JC
Semin Oncol; 1989 Apr; 16(2 Suppl 4):26-9. PubMed ID: 2540532
[No Abstract] [Full Text] [Related]
35. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
Perry MC; Ihde DC; Herndon JE; Grossbard ML; Grethein SJ; Atkins JN; Vokes EE; Green MR
Lung Cancer; 2000 Apr; 28(1):63-8. PubMed ID: 10704711
[TBL] [Abstract][Full Text] [Related]
36. [A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients].
González Larriba JL; Alberola V; Lianes P; Panizo A; Carrato A; Muñoz Quintana A; Cardenal F; Gracia JM; Moyano A; Díaz-Rubio E
Rev Clin Esp; 1994 Nov; 194(11):953-9. PubMed ID: 7846351
[TBL] [Abstract][Full Text] [Related]
37. Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer.
Ferrigno D; Buccheri G
Acta Oncol; 1996; 35(4):435-9. PubMed ID: 8695157
[TBL] [Abstract][Full Text] [Related]
38. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity.
Kanard A; Jatoi A; Castillo R; Geyer S; Schulz TK; Fitch TR; Rowland KM; Nair S; Krook JE; Kugler JW
Lung Cancer; 2004 Mar; 43(3):345-53. PubMed ID: 15165094
[TBL] [Abstract][Full Text] [Related]
39. Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin.
Gralla R; Harper P; Johnson S; Delgado FM
Ann Oncol; 1999; 10 Suppl 5():S41-5. PubMed ID: 10582138
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of efficiency and toxicity of two chemotherapy protocols in treatment of advanced non-small cell lung cancer].
Abazović AM; Sisić I; Kovcin V; Beculić H; Dervisević S; Musić M
Med Pregl; 2011; 64(7-8):368-72. PubMed ID: 21970063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
